Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 38.8% in November

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 734,600 shares, a drop of 38.8% from the October 31st total of 1,200,000 shares. Based on an average daily trading volume, of 6,700,000 shares, the short-interest ratio is presently 0.1 days.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO opened at $0.35 on Thursday. The company’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.40. Aptevo Therapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $10.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on APVO shares. StockNews.com started coverage on Aptevo Therapeutics in a research report on Saturday, November 23rd. They set a “sell” rating for the company. Roth Mkm dropped their price objective on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.